First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
{{output}}
Objective: This study aimed to evaluate the cost-effectiveness of using selpercatinib as a first-line treatment option or reserving it for second-line use versus relying exclusively on chemotherapy in managing RET fusion-positive... ...
